Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome
NCT06698848Phase 1Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2025
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoint: Montgomery Asberg Depression Rating Scale at 1 week. Started Jan 2025; status: active, not recruiting.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06698848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06698848.